CD276 was first derived from dendritic cells and the immune checkpoint in cancers; it impaired T cell–mediated anticancer immunity in ovarian cancer and destroyed the anti-PD-1 therapy in non-small cell lung cancer (30). This evidence concerns the gene PDCD1 and ovarian carcinoma.